Impact of endothelin-1 Lys198Asn polymorphism on coronary artery disease and endorgan damage in hypertensives

被引:17
作者
Popov, Aron Frederik [1 ]
Schulz, Egbert Godehard [5 ]
Hinz, Jose [3 ]
Schmitto, Jan Dieter [1 ]
Seipelt, Ralf [1 ]
Koziolek, Michael Johann [2 ]
Rosenberger, Albert [4 ]
Schoendube, Friedrich Albert [1 ]
Mueller, Gerhard Anton [2 ]
机构
[1] Univ Gottingen, Dept Cardiovasc Thorac Surg, D-37099 Gottingen, Germany
[2] Univ Gottingen, Dept Nephrol & Rheumatol, D-37099 Gottingen, Germany
[3] Univ Gottingen, Dept Anaesthesiol Emergency & Intens Care Med, D-37099 Gottingen, Germany
[4] Univ Gottingen, Dept Genet Epidemiol, D-37099 Gottingen, Germany
[5] Ctr Nephrol & Dialysis Bovenden Germany, Gottingen, Germany
关键词
endothelin-1; genetics; hypertension; polymorphism;
D O I
10.1097/MCA.0b013e32830936e5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Endothelin is the most potent endogenous vasoconstrictor and is involved in several vascular disorders such as arterial hypertension. Its intense interaction with other vasoactive hormone systems revealed the consideration about the endothelin gene as an interesting candidate for influencing the development of essential hypertension and hypertensive endorgan damage. The purpose of this study was to investigate the role of endothelin-1 Lys198Asn polymorphism in patients with severe arterial hypertension as well as associated endorgan damages. Methods In 400 hypertensive patients and 150 normotensive controls we examined the endothelin-1 Lys198Asn polymorphism by DNA sequencing and patients were divided according to their genotype (GG, GT, and TT). Moreover, the frequency of endothelin-1 Lys198Asn polymorphism was investigated with respect to the prevalence of several actual or historical endorgan damages (renal disorder, coronary artery disease, vascular events, vascular damage, and congestive heart failure) in hypertensive patients. Results Genotype distribution for endothelin-1 Lys198Asn polymorphism was 573% (GG), 41.3% (GT), and 11.43% (TT) in normotensive individuals; and in hypertensive individuals was 54.75% (GG), 43% (GT) and 2.25% (TT). Genotype distribution was unaffected in patients with severe hypertension, renal disorder, vascular events, vascular damage, and congestive heart failure. We, however, found a significant difference in hypertensive individuals with coronary artery disease and TT genotype (P=0.004). Conclusion Homozygous TT carrier contributes to a higher prevalence of coronary artery disease, especially for three-vessel disease in hypertensive individuals. Thus, the polymorphism at position 198 could serve as a possibility to differentiate high-risk subgroups in the heterogeneous population of hypertensive patients. Coron Artery Dis 19:429-434 (C) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:429 / 434
页数:6
相关论文
共 33 条
[11]   THE HUMAN ENDOTHELIN FAMILY - 3 STRUCTURALLY AND PHARMACOLOGICALLY DISTINCT ISOPEPTIDES PREDICTED BY 3 SEPARATE GENES [J].
INOUE, A ;
YANAGISAWA, M ;
KIMURA, S ;
KASUYA, Y ;
MIYAUCHI, T ;
GOTO, K ;
MASAKI, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2863-2867
[12]   Association of endothelin-1 gene variant with hypertension [J].
Jin, JJ ;
Nakura, J ;
Wu, ZH ;
Yamamoto, M ;
Abe, M ;
Tabara, Y ;
Yamamoto, Y ;
Igase, M ;
Kohara, K ;
Miki, T .
HYPERTENSION, 2003, 41 (01) :163-167
[13]   PLASMA-IMMUNOREACTIVE ENDOTHELIN IN ESSENTIAL-HYPERTENSION [J].
KOHNO, M ;
YASUNARI, K ;
MURAKAWA, KI ;
YOKOKAWA, K ;
HORIO, T ;
FUKUI, T ;
TAKEDA, T .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (06) :614-618
[14]   Seventh report of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) resetting the hypertension sails [J].
Lenfant, C ;
Chobanian, AV ;
Jones, DW ;
Roccella, EJ .
HYPERTENSION, 2003, 41 (06) :1178-1179
[15]   CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS [J].
LERMAN, A ;
EDWARDS, BS ;
HALLETT, JW ;
HEUBLEIN, DM ;
SANDBERG, SM ;
BURNETT, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (14) :997-1001
[16]   Endothelin receptor antagonism in patients with chronic heart failure [J].
Love, MP ;
Ferro, CJ ;
Haynes, WG ;
Plumpton, C ;
Davenport, AP ;
Webb, DJ ;
McMurray, JJV .
CARDIOVASCULAR RESEARCH, 2000, 47 (01) :166-172
[17]  
LUSCHER TF, 1989, J CARDIOVASC PHARM, V14, pS63
[18]   Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension [J].
Minami, S ;
Yamano, S ;
Yamamoto, Y ;
Sasaki, R ;
Nakashima, T ;
Takaoka, M ;
Hashimoto, T .
HYPERTENSION RESEARCH, 2001, 24 (06) :663-670
[19]   IMMUNOHISTOCHEMICAL DISTRIBUTION OF ENDOTHELIN IN BIOPSIES OF PEDIATRIC NEPHROTIC SYNDROME [J].
MURER, L ;
ZACCHELLO, G ;
BASSO, G ;
SCARPA, A ;
MONTINI, G ;
CHIOZZA, ML ;
ZACCHELLO, F .
AMERICAN JOURNAL OF NEPHROLOGY, 1994, 14 (03) :157-161
[20]   URINARY-EXCRETION OF ENDOTHELIN-1 IN NORMAL SUBJECTS AND PATIENTS WITH RENAL-DISEASE [J].
OHTA, K ;
HIRATA, Y ;
SHICHIRI, M ;
KANNO, K ;
EMORI, T ;
TOMITA, K ;
MARUMO, F .
KIDNEY INTERNATIONAL, 1991, 39 (02) :307-311